Understanding the biosynthesis of human IgM SAM-6 through a combinatorial expression of mutant subunits that affect product assembly and secretion.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 30 08 2023
accepted: 06 05 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 7 6 2024
Statut: epublish

Résumé

Polymeric IgMs are secreted from plasma cells abundantly despite their structural complexity and intricate multimerization steps. To gain insights into IgM's assembly mechanics that underwrite such high-level secretion, we characterized the biosynthetic process of a natural human IgM, SAM-6, using a heterologous HEK293(6E) cell platform that allowed the production of IgMs both in hexameric and pentameric forms in a controlled fashion. By creating a series of mutant subunits that differentially disrupt secretion, folding, and specific inter-chain disulfide bond formation, we assessed their effects on various aspects of IgM biosynthesis in 57 different subunit chain combinations, both in hexameric and pentameric formats. The mutations caused a spectrum of changes in steady-state subcellular subunit distribution, ER-associated inclusion body formation, intracellular subunit detergent solubility, covalent assembly, secreted IgM product quality, and secretion output. Some mutations produced differential effects on product quality depending on whether the mutation was introduced to hexameric IgM or pentameric IgM. Through this systematic combinatorial approach, we consolidate diverse overlapping knowledge on IgM biosynthesis for both hexamers and pentamers, while unexpectedly revealing that the loss of certain inter-chain disulfide bonds, including the one between μHC and λLC, is tolerated in polymeric IgM assembly and secretion. The findings highlight the differential roles of underlying non-covalent protein-protein interactions in hexamers and pentamers when orchestrating the initial subunit interactions and maintaining the polymeric IgM product integrity during ER quality control steps, secretory pathway trafficking, and secretion.

Identifiants

pubmed: 38848420
doi: 10.1371/journal.pone.0291568
pii: PONE-D-23-28036
doi:

Substances chimiques

Immunoglobulin M 0
Protein Subunits 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0291568

Informations de copyright

Copyright: © 2024 Hasegawa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Haruki Hasegawa (H)

Discovery Protein Science, Department of Large Molecule Discovery and Research Data Science, Amgen Inc., South San Francisco, CA, United States of America.

Songyu Wang (S)

Discovery Protein Science, Department of Large Molecule Discovery and Research Data Science, Amgen Inc., South San Francisco, CA, United States of America.

Eddie Kast (E)

Molecular Analytics, Department of Biologic Therapeutic Discovery, Amgen Inc., South San Francisco, CA, United States of America.

Hui-Ting Chou (HT)

Structural Biology, Department of Small Molecule Therapeutic Discovery, Amgen Inc., South San Francisco, CA, United States of America.

Mehma Kaur (M)

Discovery Protein Science, Department of Large Molecule Discovery and Research Data Science, Amgen Inc., South San Francisco, CA, United States of America.

Tanakorn Janlaor (T)

Discovery Protein Science, Department of Large Molecule Discovery and Research Data Science, Amgen Inc., South San Francisco, CA, United States of America.

Mina Mostafavi (M)

Discovery Protein Science, Department of Large Molecule Discovery and Research Data Science, Amgen Inc., South San Francisco, CA, United States of America.

Yi-Ling Wang (YL)

Discovery Protein Science, Department of Large Molecule Discovery and Research Data Science, Amgen Inc., South San Francisco, CA, United States of America.

Peng Li (P)

Discovery Protein Science, Department of Large Molecule Discovery and Research Data Science, Amgen Inc., South San Francisco, CA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH